Table 8.
Ligand-Conjugated Liposomes in Clinical Trials
| Liposome Therapeutic (Name, Therapeutic) | Intended Treatment | Targeting Agent | Molecular Target | Company | Phase |
|---|---|---|---|---|---|
| MBP-426 (oxaliplatin) | Gastroesophageal adenocarcinoma | Transferrin | Transferrin receptor | Mebiopharm Company | Phase II |
| SGT-53 (pDNA with p53 gene) | Solid tumors | Ab derivative (TfRscFv)a | Transferrin receptor | Synergene therapeutics | Phase I |
| 2B3-101 (doxorubicin) | Brain and breast cancer | Glutathione | BBB transporters | To-BBB | Phase II |
a
The targeting agent for SGT-52 is an antibody derivative [a single-chain variable fragment (scFv)] with binding affinity to the transferrin receptor (TfR).
Ab, antibody; BBB, blood–brain barrier; pDNA, plasmid DNA; TfRscFv, transferrin receptor single-chain antibody variable fragment.